Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus

Liver Transplantation

Volumn 12, Issue 4, 2006, Pages 659-664

  Dumortier, Jérôme ^a   Bernard, Sophie ^b   Bouffard, Yves ^a   Boillot, Olivier ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b LOUIS PRADEL HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HEMOGLOBIN A1C; INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; TSUKUBAENOLIDE;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DIGESTIVE SYSTEM DISEASE; DISEASE COURSE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EDEMA; FEMALE; FOLLOW UP; GINGIVA HYPERPLASIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; CYCLOSPORINE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 33645573358     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20634     Document Type: Article

References (18)

1. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003;63:1247-1297.
2. Burkhalter EL, Starzl TE, Van Thiel DH. Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. J Hepatol 1994;21:572-577.
3. Fisher A, Schwartz M, Mor E, Sheiner P, Emre S, Guy S, et al. Gastrointestinal toxicity associated with FK 506 In liver transplant recipients. Transplant Proc 1994:26:3106-3107.
4. Platz KP, Mueller AR, Blumhardt G. Bachmann S, Bechstein WO, Kahl A, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994;58:170-178.
5. Jindal RM, Sidner RA, Milgrom MI. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 1997; 16:242-257.
6. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62:920-926.
7. Emre S, Genyk Y, Schluger LK, Fishbein TM, Guy SP, Sheiner PA, et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int 2000; 13:73-78.
8. Abouljoud MS, Kumar MS, Brayman KL, Emre S, Bynon JS. Neoral rescue therapy In transplant patients with intolerance to tacrolimus. Clin Transplant 2002; 16:168-172.
9. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002;25:583-592.
10. Hricik DE, Almawi WY, Strom M. Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994;57:979-989.
11. Heisel O, Heisel P, Balshaw R Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4:583-595.
12. Bald S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001;72:1066-1072.
13. Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 2002;74:1007-1012.
14. American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 2002;25:S1-147.
15. Filler G, Neuschulz L Vollmer I. Amendt P, Hocher B. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 2000;15:867-871.
16. Uchizono Y, Iwase M, Nakamura U, Sasaki N, Goto D, Iida M. Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling. Endocrinology 2004; 145:2264-2272.
17. Baid-Agrawal S, Delmonico FL, Tolkoff-Rubin NE, Farrell M, Williams WW, Shih V, et al. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. Transplantation 2004;77: 1199-1202.
18. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk proffle. Am J Transplant 2004;4: 937-945.